TAE Life Sciences announces scientific advisory board to advance cancer research

US based TAE Life Sciences, a company pioneering a new cancer treatment platform that addresses limitations in current cancer therapy, has announced the formation of a Scientific Advisory Board to facilitate groundbreaking advancements in the emerging field of accelerator-based boron-neutron capture therapy (BNCT). 

The advisory board represents a diverse group of oncology experts from prestigious international cancer centers. Jointly, they will provide valuable clinical and research insights and input to TAE Life Sciences' product strategy and development roadmap, as well as evaluate the clinical application and potential therapeutic benefits of BNCT.

BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam. The therapy permits the destruction of cancer within the confines of the boron-laden cells while sparing adjacent healthy tissue, usually in just one or two brief treatment sessions.

"This advisory board allows us to enter a dialogue with leaders in their respective fields, addressing areas of development critical to the evolution of this novel cancer-fighting therapy," said Bruce Bauer, TAE Life Sciences CEO. "We are excited to partner with them and advance our clinical and scientific knowledge, and benefit from their support in educating clinicians to the promising benefits BNCT offers." 

BNCT marks a significant opportunity within the $1 trillion global oncology market as it presents clear advantages to conventional cancer treatments, including radiation therapy: it has the unique ability to use biophysics to target primary tumors as well as undetected microscopic cancer cells without damaging neighboring healthy tissue; it betters the patient experience by reducing treatment visits by a factor of 10, increasing comfort and reducing potential side effects compared to other treatments; and it improves treatment center care by increasing operational efficiency and allowing for thousands of patient to be treated per year.

Utilizing their state-of-the-art accelerator-based beam technology, TAE Life Sciences is developing a holistic clinical platform for the next generation of BNCT: low energy neutron beams capable of catering to unique clinical treatment protocols with an optimized beam spectrum and precise ability to modulate intensity, coupled with a practical footprint for typical hospital radiation treatment settings.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.